Extendicare Inc. (TSE:EXE - Free Report) - Research analysts at Leede Financial lifted their FY2025 earnings per share (EPS) estimates for Extendicare in a research note issued on Wednesday, November 13th. Leede Financial analyst D. Loe now expects that the company will post earnings of $1.29 per share for the year, up from their previous forecast of $0.90. The consensus estimate for Extendicare's current full-year earnings is $0.61 per share. Leede Financial also issued estimates for Extendicare's FY2026 earnings at $1.39 EPS.
Other equities analysts also recently issued research reports about the stock. Royal Bank of Canada increased their price target on shares of Extendicare from C$8.50 to C$9.50 in a report on Monday, August 19th. TD Securities upped their target price on Extendicare from C$9.50 to C$10.50 and gave the company a "hold" rating in a report on Thursday.
View Our Latest Stock Analysis on EXE
Extendicare Stock Performance
The firm has a market cap of C$862.25 million, a PE ratio of 15.19 and a beta of 1.26. The company has a quick ratio of 0.98, a current ratio of 0.60 and a debt-to-equity ratio of 305.80. The stock's fifty day moving average is C$9.27 and its 200 day moving average is C$8.16. Extendicare has a 1 year low of C$6.45 and a 1 year high of C$10.43.
Extendicare Dividend Announcement
The firm also recently announced a monthly dividend, which was paid on Friday, November 15th. Stockholders of record on Thursday, October 31st were paid a $0.04 dividend. This represents a $0.48 dividend on an annualized basis and a dividend yield of ∞. The ex-dividend date of this dividend was Thursday, October 31st. Extendicare's dividend payout ratio is presently 70.59%.
Extendicare Company Profile
(
Get Free Report)
Extendicare Inc, through its subsidiaries, provides care and services for seniors in Canada. The company offers long term care (LTC) services; and home health care services, such as nursing care, occupational, physical and speech therapy, and assistance with daily activities, as well as management, consulting, and other services to third parties.
Featured Stories
Before you consider Extendicare, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Extendicare wasn't on the list.
While Extendicare currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
